When a Chinese EO CoA Is Not an ISO 11135 Cycle File

When an international medical device distributor or private-label buyer qualifies a Chinese contract manufacturer or inspects incoming lots of single-use sterile devices, the shipping paperwork typically includes a Certificate of Analysis (CoA) and a sterilization batch release report. For ethylene oxide (EO) sterilized products—such as urology consumables, circumcision devices, staplers, and surgical kits—the standard cited on Chinese release documentation is often GB 18279.

A widespread and commercially hazardous assumption among overseas procurement managers, reinforced by automated search summaries and distributor sales collateral, is that 'GB 18279 is simply the Chinese translation of ISO 11135.' On the surface, this equivalence seems plausible. In practice, treating a Chinese GB 18279 lot release as an automatic drop-in for an ISO 11135:2014 cycle validation file exposes importers and legal manufacturers to regulatory audit failures during US FDA 510(k) reviews, European MDR technical file assessments, and hospital procurement acceptance checks.

On 14 September 2026, international supply chains sit precisely 17 days before a major Chinese regulatory milestone: the mandatory implementation of GB 18279-2023 on 1 October 2026 ¹. This guide breaks down the legal identity of Chinese EO standards, examines what each standard edition actually proves, analyzes why modified adoption (MOD) is not US FDA Recognition Number 14-529, and provides an incoming inspection checklist for distributor and hospital quality audits.

Does a GB 18279.1-2015 CoA prove ISO 11135:2014, or only the withdrawn 2007 standard?

Incoming Chinese EO sterilization CoAs delivered to overseas buyers still commonly cite GB 18279.1-2015. To understand what this document proves, inspect the official national standard catalog maintained by China's State Administration for Market Regulation (SAMR) and the National Public Service Platform for Standards Information ³².

According to SAMR's catalog record, GB 18279.1-2015 was issued on 10 December 2015, entered into force on 1 January 2017, and holds the formal status of 现行 (In Force) as of 14 September 2026. Its international standard adoption relationship (采标情况) is classified as 等同采用 (Identical Adoption / IDT) of ISO 11135-1:2007 ³¹⁵.

Herein lies the critical compliance trap. The International Organization for Standardization (ISO) formally withdrew ISO 11135-1:2007 on 7 July 2014 (catalogue 43185, stage 95.99) ⁵, replacing it with the consolidated second edition, ISO 11135:2014 (catalogue 56137) ⁶. Consequently, when a Chinese factory provides a lot CoA dated September 2026 stating compliance with GB 18279.1-2015, the manufacturer is operating entirely legally within China's domestic regulatory framework under the National Medical Products Administration (NMPA). However, from an international regulatory perspective, that certificate proves compliance only with an underlying ISO standard that was withdrawn over twelve years ago.

• What a GB 18279.1-2015 CoA proves: The sterilization lot was processed and released in accordance with the mandatory Chinese national standard in force at the time of manufacture, satisfying NMPA domestic market-release criteria and validating physical cycle parameters against principles derived from ISO 11135-1:2007.
• What a GB 18279.1-2015 CoA does not prove: It does not prove that the sterilizer or device manufacturer has implemented ISO 11135:2014; it does not prove compliance with ISO 11135:2014/Amd 1:2018; it does not satisfy FDA Recognition Number 14-529; and it does not satisfy European harmonised standard EN ISO 11135:2014+A1:2019.

Importers submitting a technical dossier to a European Notified Body or an FDA 510(k) reviewer cannot simply attach a GB 18279.1-2015 lot release sheet and assert that ISO 11135 requirements have been met. Regulators reviewing international device files require evidence that the cycle development, physical performance qualification (PPQ), and microbiological performance qualification (MPQ) adhere to the currently recognized second edition and its mandatory amendments.

What changes on 1 October 2026 when GB 18279-2023 replaces both 2015 parts, and why is MOD not Rec 14-529?

On 8 September 2023, SAMR issued GB 18279-2023 (Sterilization of health-care products — Ethylene oxide — Requirements for the development, validation and routine control of a sterilization process for medical devices) with a designated implementation date of 1 October 2026 ¹. As of 14 September 2026, the status of GB 18279-2023 on the National Standards Information Platform is 即将实施 (Pending Implementation), with exactly 17 days remaining before it becomes the governing mandatory standard across China.

When GB 18279-2023 takes effect, it executes two major regulatory shifts in China: first, it unifies the standard into a single consolidated document, completely replacing (全部代替) both the mandatory GB 18279.1-2015 requirements standard and the recommended guidance document GB/T 18279.2-2015 ⁴. Second, its standard adoption status transitions from identical adoption to 修改采用 (Modified Adoption / MOD) of ISO 11135:2014 ¹.

While this modernization closes the historical gap between China's domestic standard and ISO 11135:2014, overseas procurement specialists must recognize why a GB 18279-2023 CoA is still not equivalent to US FDA consensus recognition or European MDR presumption of conformity.

The critical divergence between GB 18279-2023 and US FDA Recognition Number 14-529 centers on Amendment 1:2018 ⁷. On the FDA Recognized Consensus Standards database, Recognition Number 14-529 (List 052, extent Complete) names ISO 11135 Second edition 2014-07-15 including Amendment 1 (2018) and its identical US national adoption ANSI AAMI ISO 11135:2014/A1:2018 ¹⁰. The public ISO title of that amendment is Revision of Annex E, Single batch release. The remainder of Annex E is paywalled and is not reconstructed here.

SAMR's catalog record for GB 18279-2023 cites modified adoption of ISO 11135:2014; it does not state identical adoption of ISO 11135:2014 including Amendment 1:2018 ¹. Because the technical difference table in the published GB is copyrighted and paywalled, an overseas auditor cannot presume from the catalog card that China's MOD version includes—or excludes—Amendment 1. A Declaration of Conformity that names Rec 14-529 solely because a Chinese factory printed GB 18279-2023 is naming the wrong instrument; it should be sent back for a Rec 14-529 string, not treated as closed.

The SAMR catalog prints 全部代替 and the 1 October 2026 implementation date; it does not print a rule that warehouse lots sterilized under GB 18279.1-2015 become illegal on that date, and it does not print a rule that every completed 2015 performance qualification must be repeated ¹³. What the card does control is which GB is the implemented mandatory national standard for China-market cycle files from 1 October 2026. GB/Z 44877-2024, a guiding technical document on parametric release, remains a sibling—not the cycle CoA—and its detailed SAMR card still omits an implementation day ¹⁴.

If a CoA says ISO 11135 with no edition, which file is missing?

A frequent deficiency encountered during incoming inspection is a Certificate of Analysis issued by a contract sterilizer or export trading house that prints a generic, undated line: Sterilization Method: Ethylene Oxide (ISO 11135). When questioned, suppliers often reply that omitting the date is standard industry practice because 'we follow the latest standard.'

In quality auditing, an undated standard reference is not an auditable cycle-file identity. ISO 13485:2016 Clause 7.5.6 requires validation of processes for production and service provision against documented procedures. Under FDA's Quality Management System Regulation, 21 CFR 820.75 is reserved and is not the current US section number; see QMSR production and process-control file review before the first commercial lot. When a CoA recites a bare 'ISO 11135' string, an auditor must ask: which specific document and edition actually governs this sterilization batch?

• Is it ISO 11135:2014 Second Edition? If so, where is the validation protocol that names that edition for cycle development, physical qualification and microbiological qualification? Cycle mechanics belong to the ISO 11135:2014 cycle validation acceptance neighbour, not this identity page.
• Is it ISO 11135:2014/Amd 1:2018? If the file claims single-batch release, demand the Rec 14-529 string that includes Amendment 1. The public title of Amd 1 is Revision of Annex E, Single batch release; this page does not reconstruct the paywalled annex.
• Is it European Harmonised Standard EN ISO 11135:2014+A1:2019? For products destined for the European Union under MDR, MDCG 2024-13 and Commission Implementing Decision (EU) 2021/1182 cite this harmonised designation ¹¹¹². A bare ISO citation does not confirm that overlay.
• Is it China GB 18279.1-2015 or GB 18279-2023? If the physical processing took place in a contract sterilization facility in Jiangsu, Shandong, or Guangdong, was the cycle officially released under the domestic GB license, with the international ISO string added merely as decorative export copy?
• Is the supplier confusing draft projects with published standards? Search results still mix unpublished drafts with the published cycle file. The third edition draft, ISO/DIS 11135 (catalogue 81509), was cancelled at stage 40.98 on 16 May 2024 ⁹. Its later project, ISO/FDIS 11135 (catalogue 90088), sits unpublished at stage 50.00 as of 12 May 2026 on the ISO catalogue ⁸. Any CoA claiming compliance with 'ISO 11135:2024' or 'ISO 11135:2026' is citing a standard that is not published.

Whenever an incoming CoA contains an undated ISO 11135 string, flag the identity cell. Request the underlying cycle validation report, verify the exact standard edition named in the protocol, and require the Certificate of Conformance to print that complete normative document.

Is YY/T 1268-2023 the China equivalent of TIR28, and why is it not the cycle CoA?

When an OEM manufacturer introduces a new product variation—such as a larger diameter circumcision stapler, a revised blister packaging configuration, or an accessory tubing set—into an established commercial EO sterilization cycle, international buyers frequently encounter confusion between primary cycle validation and product adoption.

In the United States, as analyzed in when a sample EO lot is not a commercial-lot validation, product adoption is a different Rec-number cell: AAMI TIR28:2016/(R)2020 under FDA Recognition Number 14-603 ¹⁹. The Rec 14-603 SIS describes that TIR as guidance for adopting new or modified products into an existing validated EO process and for process equivalence across equipment. It is not the Rec 14-529 cycle file, and Rec 14-529 lists TIR28 only as a supportive publication ¹⁰.

In China, the domestic counterpart to that adoption overlay is YY/T 1268-2023 (Product adoption and process equivalence for ethylene oxide sterilization) ¹³. The industry-standard catalog records issuance on 14 March 2023 and implementation on 1 May 2024; the document is already 现行 (In Force) while GB 18279-2023 is still 即将实施.

SAMR's industry-standard catalog assigns YY/T 1268-2023 the product-addition and process-equivalence cell for ethylene oxide. That is the same incoming job as Rec 14-603 / TIR28, not proof the two documents are identical. Overseas procurement teams must avoid two auditing errors:

• Error 1: Treating a Product Adoption Protocol as a Lot CoA. A YY/T 1268-2023 evaluation report is an engineering rationalization document; it is not a lot release certificate. It demonstrates that Device B can be included in the cycle validated for Device A. Routine lot release still requires a lot-specific CoA demonstrating that physical cycle parameters (gas concentration, temperature, relative humidity, dwell time, pressure profiles) were achieved during the commercial run.
• Error 2: Presuming YY/T 1268-2023 Satisfies FDA Rec 14-603. Parallel engineering purpose is not Rec 14-603. FDA's recognized designation for a US file remains AAMI TIR28:2016/(R)2020 under Rec 14-603 ¹⁹. If a Chinese manufacturer conducted product adoption under YY/T 1268-2023, the US dossier still has to address that Rec-number cell rather than treating the China industry standard as a substitute.

Does China GMP Announcement 107, remaining shelf life, or an ISO 10993-7 residual CoA close the cycle-file question?

When international buyers raise questions regarding sterilization cycle identity, Chinese suppliers frequently supply alternative regulatory and quality records in an effort to close the inquiry. Quality audit leads must recognize that these supplementary documents address distinct compliance areas and cannot substitute for primary cycle validation evidence.

Three common sibling records are regularly offered as proxies for ISO 11135 cycle validation:

• China NMPA GMP Announcement 107 Certification: As detailed in how to read China NMPA GMP Announcement 107 in a factory qualification, Announcement 107 governs medical device manufacturing practice, cleanroom controls, and sterile quality management systems in China. A factory that passes an Announcement 107 inspection possesses a verified quality management system, but that audit confirms compliance with domestic GMP regulations; it does not audit whether a specific export SKU's cycle validation protocol complies with FDA Rec 14-529 or EN ISO 11135.
• ISO 10993-7 Ethylene Oxide Residual Test Reports: As analyzed in which ISO 10993-7 edition governs an EO residual CoA in 2026, residual testing measures EO and ethylene chlorohydrin after aeration. A residual CoA that recites a milligram-per-device result answers the residual-edition cell; it does not prove that the preceding sterilization cycle achieved a 10⁻⁶ sterility assurance level, and a verbal 4 mg/device slogan is not a global 2026 benchmark.
• Remaining Shelf Life & Sterile Barrier Documentation: Under hospital tender requirements discussed in how to specify remaining shelf life on a sterile-device tender, suppliers must guarantee minimum remaining shelf-life percentages (typically 75% to 80% at delivery). Furthermore, packaging integrity must comply with ISO 11607 Amendment 1 sterile-barrier recognition. A pristine Tyvek/film blister pack and an unexpired lot date prove barrier maintenance, but they do not validate the lethality of the sterilization process that occurred inside the chamber.

Sterility assurance is a three-pillar system consisting of cycle lethality (ISO 11135), residual dissipation (ISO 10993-7), and sterile barrier integrity (ISO 11607). Neither pillar can compensate for deficiencies in another.

How should a distributor RFQ specify standard strings without scraping paywalled standards or assuming equivalence?

To prevent incoming shipment delays, customs holds, and technical dossier rejections, overseas distributors and procurement agencies must eliminate ambiguous standard citations from their initial Requests for Quotation (RFQs) and Supplier Quality Agreements.

Procurement specifications must explicitly define the standard editions required based on the final commercial destination of the device, rather than requesting 'sterilization in accordance with international standards.' The following contractual clauses should be integrated into purchasing agreements with Chinese medical device manufacturers:

1. For US-Bound Shipments: 'The Supplier shall provide evidence of ethylene oxide sterilization process validation conforming to US FDA Recognized Consensus Standard Recognition Number 14-529 (ANSI AAMI ISO 11135:2014/A1:2018 or ISO 11135:2014 including Amendment 1:2018). Each lot Certificate of Analysis shall reference the specific cycle validation protocol and report number. Product adoption, if applicable, shall be documented in accordance with AAMI TIR28:2016/(R)2020 under FDA Rec 14-603.'
2. For European Union-Bound Shipments: 'The Supplier shall provide evidence of sterilization validation in conformity with harmonised standard EN ISO 11135:2014+A1:2019 under Regulation (EU) 2017/745 (MDR) Annex I General Safety and Performance Requirements. Undated ISO 11135 citations or national standard citations (GB 18279) are not the Union overlay named in MDCG 2024-13 and Commission Implementing Decision (EU) 2021/1182.'
3. For Chinese Domestic & NMPA Distribution: 'For lots manufactured prior to 1 October 2026, sterilization validation and lot release shall comply with GB 18279.1-2015. For all lots manufactured on or after 1 October 2026, sterilization validation and lot release shall strictly comply with GB 18279-2023.'
4. Prohibition of Draft or Colliding Designations: Contracts must explicitly state that citations of cancelled drafts (ISO/DIS 11135), unpublished drafts (ISO/FDIS 11135), or unrelated numerical collisions—specifically ISO 18279:2023, which is an international standard governing brazing imperfections ¹⁶ that frequently appears as a false search result—shall result in immediate document rejection.

Worked files: Three real-world Chinese EO CoA incoming audits

To demonstrate how these principles apply during incoming dock inspections, consider three realistic scenarios involving single-use urological devices and surgical kits commonly sourced from Chinese manufacturing facilities.

Case 1: CE-marked circumcision ring citing GB 18279.1-2015 offered into a US 510(k)

A US medical device distributor seeks to license an established disposable circumcision ring system from a Chinese OEM partner. The public product page records an NMPA Class II registration (Lu Mech Reg. 20172020238), CE yes, and EO sterilization in individual blister packs for Adult and Children variants ¹⁷. That page does not name MDD versus MDR, and it does not record a Rec 14-529 declaration. For the 510(k) sterilization section, the Chinese partner submits a recent factory lot release CoA citing GB 18279.1-2015.

Audit Assessment: The GB string is not Rec 14-529. GB 18279.1-2015 identically adopts ISO 11135-1:2007, which ISO withdrew on 7 July 2014 when ISO 11135:2014 was published ³⁵. FDA Rec 14-529, entered 15 July 2019, names the 2014 second edition including Amendment 1:2018 ¹⁰. Do not file the 2015 GB CoA as if it were that Rec-number cell. Request a cycle file that names Rec 14-529, or an explanation of why a Declaration of Conformity to Rec 14-529 cannot yet be issued for the quoted configuration.

Case 2: NMPA-only stapler citing GB 18279-2023 before vs. after 1 October 2026

A regional distributor in Southeast Asia purchases NMPA-registered disposable circumcision staplers (Lu Mech Reg. 20192020192) ¹⁸. On 15 September 2026, the incoming shipping batch arrives with a factory CoA citing GB 18279-2023.

Audit Assessment: A CoA dated 15 September 2026 that already prints GB 18279-2023 is naming a standard whose SAMR status is still 即将实施 ¹. That is not proof the lot is unsterile, and it is not proof the 2023 GB is already the implemented mandatory GB. Send the file back for explanation: was the cycle validated and released against GB 18279.1-2015 with a premature 2023 header, or has the factory already executed a 2023-edition protocol during the published-but-not-yet-implemented interval? After 1 October 2026, a 2015 header on a newly executed cycle is the inverse mismatch and also needs explanation. The catalog card still does not, by itself, require repeating every completed 2015 performance qualification.

Case 3: Third-party sterilizer CoA with an undated ISO 11135 line

An EU importer receives custom sterile urology puncture kits packaged with catheters and draping. The contract sterilizer's certificate states: Process: Ethylene Oxide | Standard: ISO 11135 | Result: PASS.

Audit Assessment: Place the lot-release document on hold. The certificate provides no edition, does not say whether Amendment 1 applies, and cannot be audited against MDCG 2024-13 or the EN ISO 11135:2014+A1:2019 string in Commission Implementing Decision (EU) 2021/1182 ¹¹¹². Request a revised CoA that names the Union overlay and the matching validation protocol before treating the identity cell as closed.

Where VEMERIX fits—and where due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care. Public product pages record factory EO-sterilized single-use urological devices under domestic NMPA registrations, including the Disposable Circumcision Device (Class II, Lu Mech Reg. 20172020238, CE yes) ¹⁷, the Disposable Circumcision Stapler (Class II, Lu Mech Reg. 20192020192, factory EO, no public CE field) ¹⁸, the Circumcision Anastomat Kit (Lu Mech Reg. 20162020372), and the Disposable Sterile Circumcision Device (Lu Mech Reg. 20222021157). Those pages do not record a GB 18279-2023 certificate or a Rec 14-529 declaration.

Because VEMERIX operates both within China's domestic hospital supply chain and across international distribution channels, the company maintains transparent boundaries regarding sterilization documentation:

• China Domestic Manufacturing Truth: Public pages record EO sterilization on the circumcision SKUs named above. They do not name GB 18279.1-2015 or GB 18279-2023 as a held certificate. VEMERIX can discuss the GB actually printed on the CoA a buyer holds; this article does not invent that string.
• No Inappropriate Equivalence Claims: VEMERIX does not claim that a domestic GB 18279 CoA automatically constitutes a US FDA Rec 14-529 declaration of conformity, and the public stapler page does not record a US 510(k). Where international partners prepare localized dossiers, due diligence still begins with the named GB or ISO edition against Rec 14-529 or EN ISO 11135:2014+A1:2019.
• Contractual Clarity for Distributors: International OEM and private-label partners can request the named standard string, edition, and destination-market overlay for the quoted configuration through the VEMERIX Quality & Regulatory portal or direct commercial enquiry.

Distributor and hospital RFQ checklist: Incoming EO CoA audit gates

Before releasing an imported lot of sterile medical devices into commercial distribution or clinical use, quality teams should execute this systematic four-gate audit:

• Gate 1: Standard Edition & Jurisdiction Match. Inspect the standard number and publication year printed on the CoA. If the lot was manufactured in China before 1 October 2026 and cites GB 18279.1-2015, verify that the underlying validation matches ISO 11135-1:2007. If manufactured on or after 1 October 2026, verify that GB 18279-2023 is cited. If destined for the US or EU, confirm that the CoA or attached Declaration of Conformity specifically cites FDA Rec 14-529 (including Amendment 1:2018) or EN ISO 11135:2014+A1:2019.
• Gate 2: Rejection of Undated and Colliding Designations. Reject any certificate that recites an undated 'ISO 11135' string. Audit for numerical confusion: ensure the certificate does not cite cancelled draft ISO/DIS 11135, unpublished ISO/FDIS 11135, or brazing standard ISO 18279:2023.
• Gate 3: Sibling File Verification. Verify that the sterilization cycle CoA is supported by an independent ISO 10993-7 EO/ECH residual dissipation test report and an ISO 11607 packaging seal integrity / dye penetration report. Ensure that product adoption rationales, if utilized, are documented under AAMI TIR28 (for US files) or YY/T 1268-2023 (for China files).
• Gate 4: Batch Release Physical Parameter Traceability. Verify that the CoA records specific chamber run numbers, gas exposure dwell time, chamber temperature, relative humidity during preconditioning, and biological indicator lot numbers with incubation clearance records.

Frequently asked questions

Is GB 18279 the same as ISO 11135?
No. While both standards govern ethylene oxide sterilization, GB 18279.1-2015 is an identical adoption (IDT) of ISO 11135-1:2007 (withdrawn by ISO in 2014). GB 18279-2023 (mandatory from 1 October 2026) is a modified adoption (MOD) of ISO 11135:2014. Neither Chinese standard is an identical adoption of ISO 11135:2014 including Amendment 1:2018, which is required under US FDA Recognition Number 14-529.

Is a GB 18279.1-2015 CoA still valid in China on 14 September 2026?
Yes. GB 18279.1-2015 remains the in-force mandatory national standard in China until 1 October 2026. The SAMR catalog does not, by itself, make a 2015 CoA dated 14 September 2026 illegal in China, and it does not convert that CoA into Rec 14-529 or EN ISO 11135:2014+A1:2019.

Does GB 18279-2023 include ISO 11135:2014 Amendment 1?
SAMR's public catalog records GB 18279-2023 as a modified adoption of ISO 11135:2014 without citing Amendment 1:2018. Because modified adoptions can contain technical differences, and the difference table is paywalled, auditors cannot assume Amendment 1 is fully adopted or fully excluded from the catalog card alone.

Is FDA Recognition Number 14-529 the same as a Chinese GB 18279 CoA?
No. FDA Rec 14-529 specifically mandates ISO 11135 Second Edition (2014-07-15) including Amendment 1:2018 or ANSI AAMI ISO 11135:2014/A1:2018. A Chinese domestic GB 18279 certificate is not recognized by the US FDA.

What is the latest version of ISO 11135, and is ISO/FDIS 11135 the cycle file?
The current published international standard is ISO 11135:2014 including Amendment 1:2018. The third edition draft, ISO/FDIS 11135 (catalogue 90088), remains unpublished at stage 50.00 as of the 12 May 2026 catalogue date and cannot be cited as the cycle file. The earlier draft ISO/DIS 11135 was cancelled in May 2024.

Does YY/T 1268-2023 replace TIR28 for a US file?
No. YY/T 1268-2023 is China's industry standard for product adoption and process equivalence. Parallel purpose is not Rec 14-603. A US file that claims product adoption still has to name AAMI TIR28:2016/(R)2020 under Rec 14-603.

Does VEMERIX have a GB 18279-2023 or Rec 14-529 certificate?
Public VEMERIX circumcision product pages record factory EO sterilization and the NMPA registrations cited above. They do not record a GB 18279-2023 certificate or a Rec 14-529 declaration. For overseas dossiers, request the named GB or ISO edition on the CoA the quoted configuration actually holds, plus the destination-market overlay.

Does an NMPA registration replace Rec 14-529 or EN ISO 11135:2014+A1:2019?
No. An NMPA medical device registration confirms authorization for the Chinese domestic market based on Chinese national standards. It does not confer presumption of conformity with US FDA consensus standards or European Union MDR harmonised standards.